Center for Continuing Education
About The Cleveland Clinic Center for Continuing Education | Call or Email Us | About The Cleveland Clinic
Live Cleveland Clinic CME Courses |  Regularly Scheduled Series (RSS) Registration | Regulary Scheduled Series (RSS) Schedule (pdf)
Disease Management Project Clinical Decisions Cases |  Hepatitis C Management |  Managing Problem Patients with Anti-TNF Inhibitors |  More
Medicine Today Series |  B Cell Series |  Emerging Therapies in Heart Disease Webcast Series |  More
Disease Management Project |  CCJM 1-Minute Consult |  Pharmacotherapy Update Newsletter |  Algorithms for the MICU |  More
Cleveland Clinic Foundation CME Home Contact Us Live CME Courses Online CME Topics Webcasts Online Medical Publications my CME Search Sitemap e-mail Newsletter
Midlife Menopause Management: Assessing Risks and Benefits, Individualizing Strategies

How to Obtain AMA
PRA Category 1
Credit(s)™

  1. Read the
    CME journal supplement.
  2. Take the CME posttest.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized
    CME certificate.

 


 

   
 
Release Date: May 1, 2008 Expiration Date: May 1, 2010
 

Technical Requirements
(will appear in new window)

 

Estimated Time of Completion

2 hours 30 minutes

Description / Overview

This activity is based on the proceedings of a roundtable convened at the Cleveland Clinic on January 17, 2008, by the Cleveland Clinic Journal of Medicine. It examines how and why the management of vasomotor symptoms and other menopause-related health issues should be tailored to the individual woman, based on her assessment of her most bothersome symptom(s) and her personal priorities regarding risks, benefits, and quality of life.

Objectives

At the conclusion of this activity, the participant will be able to:

  1. Compare and contrast new information on the cardiovascular effects of postmenopausal hormone therapy in younger, recently menopausal women as opposed to older, late-postmenopausal women
  2. Better understand menopausal risk assessment and explain the need to individualize therapy for symptomatic women
  3. Describe the controversies surrounding menopausal hormone therapy and avoid misapplying data derived from older women to younger women
  4. Recognize the problem of vasomotor instability in symptomatic peri- and postmenopausal women and the availability of new therapeutic options—both hormonal and nonhormonal—to deal with common menopausal symptoms.

Target Audience

This activity is intended for internists, cardiologists, and other physicians who care for menopausal and postmenopausal women.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

Activity Director

Holly L. Thacker, MD, FACP
Director, Women’s Health Center, Women’s Health and Breast Pavilion,
   OB/GYN & Women’s Health Institute
Associate Professor, Cleveland Clinic Lerner College
   of Medicine at Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Author / Faculty

Margery Gass, MD; Howard N. Hodis, MD; Marjorie R. Jenkins, MD;
Margaret McKenzie, MD, FACOG
; Andrea L. Sikon, MD, FACP

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Margery Gass, MD
  Consulting Wyeth Pharmaceuticals; Upsher-Smith; Eli Lilly; Procter & Gamble; Palatin Technologies; Esprit Pharma; Roche; Merck; Novartis
 
  Clinical Trial Funding Wyeth Pharmaceuticals; Boehringer Ingelheim; Procter & Gamble; Organon; Roche
 
Marjorie R. Jenkins, MD
  Teaching and Speaking Pfizer
 
Holly L. Thacker, MD, FACP
  Teaching and Speaking Procter & Gamble; Sanofi-Aventis; Bayer; Wyeth Pharmaceuticals; Novartis; Esprit Pharma

The following faculty has indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:

Howard N. Hodis, MD
Margaret McKenzie, MD, FACOG
Andrea L. Sikon, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:


Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and the Cleveland Clinic Journal of Medicine.

Contact Information | Privacy Policy | Disclaimer

Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.